| scholarly article | Q13442814 |
| P2093 | author name string | Li Li | |
| Liang Chen | |||
| Yang Du | |||
| Xinjian Chen | |||
| Jie Tian | |||
| Zhifeng Shi | |||
| Dehui Xiang | |||
| P2860 | cites work | Real-time bioluminescence and tomographic imaging of gastric cancer in a novel orthotopic mouse model | Q39381752 |
| Downregulation of Akt and FAK phosphorylation reduces invasion of glioblastoma cells by impairment of MT1-MMP shuttling to lamellipodia and downregulates MMPs expression | Q39601171 | ||
| Tissue inhibitor of metalloproteinase-3 expression from an oncolytic adenovirus inhibits matrix metalloproteinase activity in vivo without affecting antitumor efficacy in malignant glioma. | Q40360926 | ||
| Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells | Q40600919 | ||
| The future of therapy for glioblastoma | Q40855370 | ||
| Assessment of efficacy of antifungals against Aspergillus fumigatus: value of real-time bioluminescence imaging. | Q41441699 | ||
| Changing views of the role of matrix metalloproteinases in metastasis | Q41592276 | ||
| Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging | Q44189640 | ||
| Bioluminescence and MR Imaging of the Safety and Efficacy of Vascular Disruption in Gliomas | Q48444978 | ||
| Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion. | Q54425576 | ||
| Type IV collagenase (M(r) 72,000) expression in human prostate: benign and malignant tissue | Q72069125 | ||
| Increased incidence of matrix metalloproteinases in urine of cancer patients | Q74427915 | ||
| Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma | Q24632791 | ||
| Collagenolytic activity in amphibian tissues: a tissue culture assay | Q24648397 | ||
| Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma | Q27860910 | ||
| Matrix metalloproteinases | Q28140451 | ||
| Uniqueness theorems in bioluminescence tomography | Q28282938 | ||
| New functions for the matrix metalloproteinases in cancer progression | Q29547738 | ||
| Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group | Q30584392 | ||
| Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse | Q30647642 | ||
| Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies | Q33330748 | ||
| Orthotopic models are necessary to predict therapy of transplantable tumors in mice | Q33649321 | ||
| Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues. Clinical and experimental applications | Q33692926 | ||
| Matrix metalloproteinases: biologic activity and clinical implications | Q33849967 | ||
| Chemotherapy for high-grade gliomas | Q33898570 | ||
| In vivo molecular target assessment of matrix metalloproteinase inhibition | Q33949202 | ||
| Matrix metalloproteinases: molecular aspects of their roles in tumour invasion and metastasis | Q34013787 | ||
| Molecular imaging of cardiac cell transplantation in living animals using optical bioluminescence and positron emission tomography | Q34134449 | ||
| Advances in in vivo bioluminescence imaging of gene expression | Q34138770 | ||
| Metastatic potential correlates with enzymatic degradation of basement membrane collagen | Q34251422 | ||
| Bioluminescence imaging in vivo – application to cancer research | Q34266251 | ||
| Matrix metalloproteinases: they're not just for matrix anymore! | Q34360566 | ||
| Abl Kinases Are Required for Invadopodia Formation and Chemokine-induced Invasion | Q34401096 | ||
| Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M & B 39831), a novel drug with potential as an alternative to dacarbazine | Q34691516 | ||
| Rapid and quantitative assessment of cancer treatment response using in vivo bioluminescence imaging | Q34786078 | ||
| Inhibition of angiogenesis by non-toxic doses of temozolomide | Q35213979 | ||
| Advancing molecular therapies through in vivo bioluminescent imaging | Q35215280 | ||
| Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model | Q35665035 | ||
| Comparative Analysis of Matrix Metalloproteinase Family Members Reveals That MMP9 Predicts Survival and Response to Temozolomide in Patients with Primary Glioblastoma | Q35972486 | ||
| Molecular mechanisms of glioma cell migration and invasion | Q36021576 | ||
| Looking and listening to light: the evolution of whole-body photonic imaging | Q36070062 | ||
| A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse | Q36621800 | ||
| Inhibition of MMP14 potentiates the therapeutic effect of temozolomide and radiation in gliomas. | Q37236243 | ||
| P433 | issue | 7 | |
| P304 | page(s) | 3193-3207 | |
| P577 | publication date | 2018-06-20 | |
| P1433 | published in | Biomedical Optics Express | Q4915117 |
| P1476 | title | Prediction of the anti-glioma therapeutic effects of temozolomide through in vivo molecular imaging of MMP expression. | |
| P478 | volume | 9 |
Search more.